Korean Journal of Family Medicine (가정의학회지)

The Korean Academy of Family Medicine (대한가정의학회)
권호 표지
DOI QR코드

DOI QR Code

Aspirin Usage Based on Evidence for the Prevention of Cardio-Cerebrovascular Disease

심뇌혈관질환 예방을 위한 아스피린의 근거중심 사용법

Kim, Young-Sang;Kim, Kyoung-Kon;Hwang, In-Cheol
김영상;김경곤;황인철

  • Published : 20090400
⟨ Previous Next ⟩

Abstract

Aspirin is well known for its central role in preventing cardio cerebrovascular diseases as an antiplatelet agent. However besides its favorable effects, one must also be fully aware of its side effects such as gastrointestinal complications or cerebral hemorrhage. Particularly when prescribing to Koreans, one must be highly cautious, considering the higher prevalence of helicobacter pylori infection and the contribution of hemorrhagic stroke as a major part of cerebral disease in Korean. Currently the guideline for secondary prevention of cardio cerebrovascular diseases is relatively well established, while the consensus for primary prevention is still controversial. The purpose of this paper would be to summarize the evidence of aspirin usage in preventing cardio cerebrovascular diseases, examine the additional factors one must consider, and help primary physician prescribing aspirin appropriately.

아스피린은 심뇌혈관질환 예방에 사용하는 항 혈소판제 중 가장 중추적인 역할을 하는 약제이지만, 긍정적 효과 이외에 위장관계 합병증이나 뇌출혈 등의 부작용이 적지 않다. 특히, 한국인에서는 헬리코박터균 감염률이 높고, 뇌혈관질환 중 뇌출혈이 차지하는 비중이 매우 크기 때문에 그 사용에 있어 보다 신중해야 할 것이다. 현재 심뇌혈관질환의 이차예방에 대해서는 확립된 지침이 있지만, 일차예방에 대해서는 아직도 논란이 많다. 본 고에서는 지금까지 발표된 아스피린의 심뇌혈관질환 예방에 대한 효과를 검토하고 아스피린을 사용할 때 고려해야 할 몇 가지 사항들을 고찰함으로써 실제 임상에서 아스피린의 현명한 사용에 도움이 되고자 한다.

Keywords

References

  1. Park KA. Statistical analytic data of mortality & causes of deaths, 2007. Daejeon: Korea National Statistical Office; 2008
  2. Blaha MJ, Bansal S, Rouf R, Golden SH, Blumenthal RS, Defilippis AP. A practical 'ABCDE' approach to the metabolic syndrome. Mayo Clin Proc 2008; 83: 932-41 https://doi.org/10.4065/83.8.932
  3. Korea Centers for Disease Control and Prevention. The healthy lifestyle for prevention of cardio cerebrovascular diseases - nine preventive rules: Joint announcement of the Government and the Institute. Seoul: Korea Centers for Disease Control and Prevention; 2008
  4. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition 1997; 13: 65 https://doi.org/10.1016/0899-9007(97)90878-9
  5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47 https://doi.org/10.1161/01.CIR.97.18.1837
  6. Asia Pacific Cohort Studies Collaboration, Barzi F, Patel A, Gu D, Sritara P, Lam TH, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007; 61: 115-21 https://doi.org/10.1136/jech.2005.044842
  7. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8 https://doi.org/10.1016/S0049-3848(03)00379-7
  8. Collaborative overview of randomised trials of antiplatelet therapy- I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:81-106 https://doi.org/10.1136/bmj.308.6921.81
  9. Yim JY, Choi SH, Park MJ, Kim YS, Lim SH, Choi KR, et al. Seroprevalence of Helicobacter pylori in health check-up subjects. Korean J Med 2006; 70: 636-42
  10. Park HS, Kang MJ, Huh JT. Recent epidemiological trends of stroke. J Korean Neurosurg Soc 2008; 43: 16-20 https://doi.org/10.3340/jkns.2008.43.1.16
  11. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-43 https://doi.org/10.1016/j.jacc.2007.11.080
  12. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B-15B https://doi.org/10.1016/0002-9149(91)90379-Y
  13. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-84 https://doi.org/10.1161/01.CIR.72.6.1177
  14. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-909 https://doi.org/10.1161/CIRCULATIONAHA.108.191087
  15. Fauci AS, Harrison TR. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Medical; 2008
  16. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129-35 https://doi.org/10.1056/NEJM198907203210301
  17. Mosca L. Aspirin chemoprevention: one size does not fit all. Circulation 2008; 117: 2844-6 https://doi.org/10.1161/CIRCULATIONAHA.108.778407
  18. Kikano GE, Brown MT. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. Mayo Clin Proc 2007; 82: 583-93 https://doi.org/10.4065/82.5.583
  19. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):S776-814 https://doi.org/10.1378/chest.08-0685
  20. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39: 1647-52 https://doi.org/10.1161/STROKEAHA.107.189063
  21. Sobel M, Verhaeghe R; American College of Chest Physicians; American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): S815-843 https://doi.org/10.1378/chest.08-0686
  22. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-6 https://doi.org/10.1136/bmj.296.6618.313
  23. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-41 https://doi.org/10.1016/S0140-6736(97)11475-1
  24. Hansson L, Zanchett i A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62 https://doi.org/10.1016/S0140-6736(98)04311-6
  25. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95 https://doi.org/10.1016/S0140-6736(00)03539-X
  26. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10 https://doi.org/10.1001/archinte.163.17.2006
  27. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304 https://doi.org/10.1056/NEJMoa050613
  28. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-13 https://doi.org/10.1001/jama.295.3.306
  29. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008; 117: 2875-83 https://doi.org/10.1161/CIRCULATIONAHA.107.735340
  30. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53 https://doi.org/10.1016/S1474-4422(03)00266-7
  31. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998; 352: 1801-7 https://doi.org/10.1016/S0140-6736(98)03454-0
  32. Ueda K, Hasuo Y, Kiyohara Y, Wada J, Kawano H, Kato I, et al. Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke 1988; 19: 48-52 https://doi.org/10.1161/01.STR.19.1.48
  33. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-10 https://doi.org/10.1056/NEJM198904063201405
  34. Epidemiology of cerebrovascular disease in Korea-a Collaborative Study, 1989-1990. Korean Neurological Association. J Korean Med Sci 1993; 8: 281-9
  35. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10(Suppl): S1-10
  36. Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 2004; 117: 459-68 https://doi.org/10.1016/j.amjmed.2004.04.017
  37. Ahn KA , Yun JE, Cho ER, Nam CM, Jang Y, Jee SH. Framingham equation model overestimates risk of ischemic heart disease in Korean men and women. Korean J Epidemiol 2006; 28: 162-70
  38. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-72 https://doi.org/10.7326/0003-4819-136-2-200201150-00016
  39. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996; 25: 279-98 https://doi.org/10.1016/S0889-8553(05)70247-8
  40. van Oijen MG, Dieleman JP, Laheij RJ, Sturkenboom MC, Jansen JB, Verheugt FW. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008; 6: 309-13 https://doi.org/10.1016/j.cgh.2007.12.018
  41. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037-46 https://doi.org/10.1111/j.1572-0241.1998.00588.x
  42. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000; 14: 529-34 https://doi.org/10.1046/j.1365-2036.2000.00739.x
  43. Goldstein JL, Huang B, Amer F, Christopoulos NG. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004; 26: 1637-43 https://doi.org/10.1016/j.clinthera.2004.10.002
  44. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bitt man RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9 https://doi.org/10.7326/0003-4819-123-4-199508150-00001
  45. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forne M, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-15 https://doi.org/10.1111/j.1572-0241.2006.01062.x
  46. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-10 https://doi.org/10.1111/j.1572-0241.2006.00499.x
  47. Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 1091-7 https://doi.org/10.1111/j.1365-2036.2004.02246.x
  48. Kim JW. NSAID-induced Gastroenteropathy. Korean J Gastroenterol 2008; 52: 134-41
  49. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801 https://doi.org/10.1111/j.1365-2036.2005.02649.x
  50. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-86 https://doi.org/10.1046/j.1365-2036.2002.01230.x
  51. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 497-506 https://doi.org/10.1046/j.1365-2036.2002.01197.x
  52. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-8 https://doi.org/10.1056/NEJMoa012877
  53. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73 https://doi.org/10.1056/NEJM200103293441304
  54. American Gastroenterological Association, Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006; 4: 1082-9 https://doi.org/10.1016/j.cgh.2006.04.010
  55. Lee JY, Kim W, Gwak GY, Park SC, Ye BD, Lee SH, et al. Reinfection rate and clinical manifestation of helicobacter pylori-positive peptic ulcer disease after triple therapy containing clarithromycin. Korean J Gastroenterol 2002; 39: 93-100
  56. Kim CT, Kang PS, Lee KS, Hwan TY. Helicobacter pylori reinfection rate and its related factors after successful eradication: 4-year follow-up in a Korean rural community. Korean J Gastroenterol 2005; 46: 39-47
  57. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41 https://doi.org/10.1001/jama.2008.623
  58. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39 https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  59. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006; 98: 746-50 https://doi.org/10.1016/j.amjcard.2006.04.012
  60. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371: 1800-9 https://doi.org/10.1016/S0140-6736(08)60768-0
  61. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 1997; 46: 2096-101 https://doi.org/10.2337/diabetes.46.12.2096
  62. Albertini JP, Valensi P, Lormeau B, Aurousseau MH, Ferriere F, Attali JR, et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM: effect of intensive insulin treatment. Diabetes Care 1998; 21: 1008-13 https://doi.org/10.2337/diacare.21.6.1008
  63. Davi G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149-63 https://doi.org/10.1016/j.chemphyslip.2003.10.001
  64. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-9 https://doi.org/10.1001/archinte.167.15.1593
  65. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8 https://doi.org/10.1136/bmj.39430.529549.BE
  66. Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005; 6: 2027-45 https://doi.org/10.1517/14656566.6.12.2027
  67. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17 https://doi.org/10.1016/S0140-6736(06)68040-9
  68. Lee YK, Kim HS, Park JY, Kang HJ. Incidence of aspirin resistance in the patient group of a university hospital in Korea. Korean J Lab Med 2008; 28: 251-7 https://doi.org/10.3343/kjlm.2008.28.4.251
  69. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17 https://doi.org/10.1056/NEJMoa003199
  70. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4 https://doi.org/10.1016/S0140-6736(03)12509-3
  71. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008; 101: 1060-3 https://doi.org/10.1016/j.amjcard.2007.11.054
  72. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370: 2138-51 https://doi.org/10.1016/S0140-6736(07)61909-6
  73. Jones R, Rubin G, Berenbaum F, Scheiman J. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 2008; 121: 464-74 https://doi.org/10.1016/j.amjmed.2008.01.045
  74. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-8 https://doi.org/10.1016/j.amjcard.2006.01.059
  75. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81 https://doi.org/10.1016/S0140-6736(00)02212-1
  76. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53 https://doi.org/10.1056/NEJM200001203420301
  77. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8 https://doi.org/10.1016/S0140-6736(03)14286-9
  78. Meune C, Mourad JJ, Bergmann JF, Spaulding C. Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance. J Renin Angiotensin Aldosterone Syst 2003; 4: 149-54 https://doi.org/10.3317/jraas.2003.023
  79. Brunner-La Rocca HP. Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy finally resolved? Chest 2003; 124: 1192-4 https://doi.org/10.1378/chest.124.4.1192
  80. Aumegeat V, Lamblin N, de Groote P, Mc Fadden EP, Millaire A, Bauters C, et al. Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with Angiotensin-converting enzyme inhibitors. Chest 2003; 124: 1250-8 https://doi.org/10.1378/chest.124.4.1250

Cited by

  1. 지역사회에 거주하는 만성질환 노인의 약물 오·남용행위 경험 vol.16, pp.9, 2009, https://doi.org/10.5392/jkca.2016.16.09.791